Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Clinical trial NCT07223541 · RECRUITING

Trial details

NCT number: NCT07223541
Sponsor: University of Oklahoma
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Clear Cell Renal Cell Carcinoma

Start date: 2026-01-15
Primary completion: 2029-08-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.